# US 2020/0392247 A1 · T cell-antigen coupler with y182t mutation and methods and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392247 A1
- Document ID: US20200392247A1
- Status: Published application
- Kind: A1
- Application number: 16/753,577
- Filed: 2018-10-10
- Published: 2020-12-17
- Earliest claimed: 2017-10-12
- Assignees: McMaster University
- Applicants: McMaster University
- Inventors: Christopher W. HELSEN; Jonathan BRAMSON; Anna DVORKIN-GHEVA; Galina F. DENISOVA; Ksenia BEZVERBNAYA; Kenneth Anthony MWAWASI
- Web page: https://patentgrep.com/patent/US20200392247A1

## CPC

- C07K 16/3061: {Blood cells}
- C07K 16/32: against translation products of oncogenes
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/385: Haptens or antigens, bound to carriers
- A61P 35/00: Antineoplastic agents
- C07K 14/525: Tumour necrosis factor [TNF]
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70514: {CD4}
- C07K 14/70517: {CD8}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2818: {against CD28 or CD152}
- A61K 35/00: Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2318/20: Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A trifunctional molecule comprising a target-specific ligand, a ligand that binds a protein associated with the TCR complex and a T cell receptor signaling domain polypeptide is provided. The ligand that binds a protein associated with a TCR complex is UCHT1 with a Y182T mutation. Engineering T cells with this novel receptor engenders antigen specific activation of numerous T cell functions, including cytokine production, degranulation and cytolysis.

## Claims

### Claim 1

A nucleic acid sequence encoding a Trifunctional T cell-antigen coupler (Tri-TAC) comprising:
(a) a first polynucleotide sequence encoding a ligand that selectively binds a target antigen;
(b) a second polynucleotide sequence encoding a UCHT1 ligand with a Y182T mutation comprising an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 26 that binds a protein associated with a T cell receptor (TCR) complex; and
(c) a third polynucleotide sequence encoding a TCR signaling domain polypeptide.

### Claim 2 (depends on 1)

The nucleic acid sequence of claim 1, wherein the amino acid sequence comprises SEQ ID NO: 26.

### Claim 3

A nucleic acid sequence encoding a T cell-antigen coupler (Tri-TAC) comprising:
(a) a first polynucleotide sequence encoding a ligand that selectively binds a target antigen;
(b) a second polynucleotide sequence encoding a humanized variant of UCHT1 (huUCHT1) ligand comprising an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 29 that binds a protein associated with a T cell receptor (TCR) complex; and
(c) a third polynucleotide sequence encoding a TCR signaling domain polypeptide.

### Claim 4 (depends on 3)

The nucleic acid sequence of claim 3, wherein the amino acid sequence comprises SEQ ID NO: 29

### Claim 5

A nucleic acid sequence encoding a T cell-antigen coupler (Tri-TAC) comprising:
(a) a first polynucleotide sequence encoding a ligand that selectively binds a target antigen;
(b) a second polynucleotide sequence encoding a humanized variant of UCHT1 (huUCHT1) ligand with a Y177T mutation comprising an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 28 that binds a protein associated with a T cell receptor (TCR) complex; and
(c) a third polynucleotide sequence encoding a TCR signaling domain polypeptide.

### Claim 6 (depends on 5)

The nucleic acid sequence of claim 5, wherein the amino acid sequence comprises SEQ ID NO: 28.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The nucleic acid sequence of any one of claims 1-6, wherein the ligand specifically binds the target antigen.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The nucleic acid sequence of any one of claims 1-7, wherein the ligand is an ankyrin repeat (DARPin) polypeptide.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7)

The nucleic acid sequence of any one of claims 1-7, wherein the ligand is a single chain variable fragment (scFv).

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The nucleic acid sequence of any one of claims 1-9, wherein the target antigen is a tumor antigen.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The nucleic acid sequence of any one of claims 1-10, wherein the tumor antigen is a HER-2 antigen.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The nucleic acid sequence of any one of claims 1-10, wherein the tumor antigen is a BCMA antigen.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The nucleic acid sequence of any one of claims 1-13, wherein the protein associated with a TCR complex is CD3, preferably CD3ε.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The nucleic acid sequence of any one of claims 1-13, wherein the TCR signaling domain polypeptide comprises a transmembrane domain and a cytosolic domain.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The nucleic acid sequence of any one of claims 1-14, wherein the TCR signaling domain polypeptide comprises a transmembrane domain and a cytosolic domain of a TCR co-receptor.

### Claim 16 (depends on 15)

The nucleic acid sequence of claim 15, wherein the TCR co-receptor is CD4.

### Claim 17 (depends on 16)

The nucleic acid sequence of claim 16, wherein the TCR co-receptor is CD8, preferably CD8α.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The nucleic acid sequence of any one of claims 1-17, wherein the first polypeptide, the second polypeptide, and the third polypeptide are directly fused.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The nucleic acid sequence of any one of claims 1-17, wherein the first polypeptide and the second polypeptide are directly fused, and joined to the third polypeptide by a linker.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The nucleic acid sequence of any one of claims 1-17, wherein the second polypeptide and the third polypeptide are directly fused, and joined to the first polypeptide by a linker.

### Claim 21 (depends on 19, 20)

The nucleic acid sequence of any one of claims 19-20, wherein the linker is a peptide linker, preferably a peptide linker comprising 5 to 30 amino acids, more preferably 5 amino acids, 10 amino acids, or 15 amino acids.

### Claim 22 (depends on 21)

The nucleic acid sequence of claim 21, wherein the peptide linker comprises a G4S3 linker.

### Claim 23

A nucleic acid sequence encoding an anti-HER-2 Trifunctional T cell-antigen coupler (anti-HER-2 Tri-TAC) comprising:
(a) a first polynucleotide sequence encoding a ligand that selectively binds a HER-2 antigen;
(b) a second polynucleotide sequence encoding:
(i) a UCHT1 ligand with a Y182T mutation comprising an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 26 that binds a protein associated with a T cell receptor (TCR) complex,
(ii) a humanized variant of UCHT1 (huUCHT1) ligand comprising an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 29 that binds a protein associated with a T cell receptor (TCR) complex, or
(iii) a humanized variant of UCHT1 (huUCHT1) ligand with a Y177T mutation comprising an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 28 that binds a protein associated with a T cell receptor (TCR) complex; and
(c) a third polynucleotide sequence encoding a TCR signaling domain polypeptide.

### Claim 24 (depends on 23)

The nucleic acid sequence of claim 23, wherein the amino acid sequence comprises SEQ ID NO: 26.

### Claim 25 (depends on 23)

The nucleic acid sequence of claim 23, wherein the amino acid sequence comprises SEQ ID NO: 29.

### Claim 26 (depends on 23)

The nucleic acid sequence of claim 23, wherein the amino acid sequence comprises SEQ ID NO: 28.

### Claim 27 (depends on 23, 24, 25, 26)

The nucleic acid sequence of any one of claims 23-26, wherein the ligand specifically binds the HER-2 antigen.

### Claim 28 (depends on 23, 24, 25, 26, 27)

The nucleic acid sequence of any one of claims 23-27, wherein the ligand is an ankyrin repeat (DARPin) polypeptide.

### Claim 29 (depends on 23, 24, 25, 26, 27, 28)

The nucleic acid sequence of any one of claims 23-28, wherein the HER-2 antigen is expressed on a cancer cell.

### Claim 30 (depends on 23, 24, 25, 26, 27, 28, 29)

The nucleic acid sequence of any one of claims 23-29, wherein the protein associated with a TCR complex is CD3, preferably CD3ε.

### Claim 31 (depends on 23, 24, 25, 26, 27, 28, 29, 30)

The nucleic acid sequence of any one of claims 23-30, wherein the TCR signaling domain polypeptide comprises a transmembrane domain and a cytosolic domain.

### Claim 32 (depends on 23, 24, 25, 26, 27, 28, 29, 30, 31)

The nucleic acid sequence of any one of claims 23-31, wherein the TCR signaling domain polypeptide comprises a transmembrane domain and a cytosolic domain of a TCR co-receptor.

### Claim 33 (depends on 32)

The nucleic acid sequence of claim 32, wherein the TCR co-receptor is CD4.

### Claim 34 (depends on 32)

The nucleic acid sequence of claim 32, wherein the TCR co-receptor is CD8, preferably CD8α.

### Claim 35 (depends on 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The nucleic acid sequence of any one of claims 23-34, wherein the first polypeptide, the second polypeptide, and the third polypeptide are directly fused.

### Claim 36 (depends on 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The nucleic acid sequence of any one of claims 23-34, wherein the first polypeptide and the second polypeptide are directly fused, and joined to the third polypeptide by a linker.

### Claim 37 (depends on 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The nucleic acid sequence of any one of claims 23-34, wherein the second polypeptide and the third polypeptide are directly fused, and joined to the first polypeptide by a linker.

### Claim 38 (depends on 35, 36, 37)

The nucleic acid sequence of any one of claims 35-37, wherein the linker is a peptide linker, preferably a peptide linker comprising 5 to 30 amino acids, more preferably 5 amino acids, 10 amino acids, or 15 amino acids.

### Claim 39 (depends on 38)

The nucleic acid sequence of claim 38, wherein the peptide linker comprises a G4S3 linker.

### Claim 40

A nucleic acid sequence encoding an anti-BCMA Trifunctional T cell-antigen coupler (anti-BCMA Tri-TAC) comprising:
(a) a first polynucleotide sequence encoding a ligand that selectively binds a BCMA antigen;
(b) a second polynucleotide sequence encoding:
(i) a UCHT1 ligand with a Y182T mutation comprising an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 26 that binds a protein associated with a T cell receptor (TCR) complex,
(ii) a humanized variant of UCHT1 (huUCHT1) ligand comprising an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 29 that binds a protein associated with a T cell receptor (TCR) complex, or
(iii) a humanized variant of UCHT1 (huUCHT1) ligand with a Y177T mutation comprising an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 28 that binds a protein associated with a T cell receptor (TCR) complex; and
(c) a third polynucleotide sequence encoding a TCR signaling domain polypeptide.

### Claim 41 (depends on 40)

The nucleic acid sequence of claim 40, wherein the amino acid sequence comprises SEQ ID NO: 26.

### Claim 42 (depends on 40)

The nucleic acid sequence of claim 40, wherein the amino acid sequence comprises SEQ ID NO: 29.

### Claim 43 (depends on 40)

The nucleic acid sequence of claim 40, wherein the amino acid sequence comprises SEQ ID NO: 28.

### Claim 44 (depends on 40, 41, 42, 43)

The nucleic acid sequence of any one of claims 40-43, wherein the ligand specifically binds the BCMA antigen.

### Claim 45 (depends on 40, 41, 42, 43, 44)

The nucleic acid sequence of any one of claims 40-44, wherein the ligand is a single chain variable fragment (scFv).

### Claim 46 (depends on 44)

The nucleic acid sequence of claim 44, wherein the BCMA antigen is expressed on a cancer cell.

### Claim 47 (depends on 40, 41, 42, 43, 44, 45, 46)

The nucleic acid sequence of any one of claims 40-46, wherein the protein associated with a TCR complex is CD3, preferably CD3∈.

### Claim 48 (depends on 40, 41, 42, 43, 44, 45, 46, 47)

The nucleic acid sequence of any one of claims 40-47, wherein the TCR signaling domain polypeptide comprises a transmembrane domain and a cytosolic domain.

### Claim 49 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48)

The nucleic acid sequence of any one of claims 40-48, wherein the TCR signaling domain polypeptide comprises a transmembrane domain and a cytosolic domain of a TCR co-receptor.

### Claim 50 (depends on 49)

The nucleic acid sequence of claim 49, wherein the TCR co-receptor is CD4.

### Claim 51 (depends on 49)

The nucleic acid sequence of claim 49, wherein the TCR co-receptor is CD8, preferably CD8α.

### Claim 52 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The nucleic acid sequence of any one of claims 40-51, wherein the first polypeptide, the second polypeptide, and the third polypeptide are directly fused.

### Claim 53 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The nucleic acid sequence of any one of claims 40-51, wherein the first polypeptide and the second polypeptide are directly fused, and joined to the third polypeptide by a linker.

### Claim 54 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The nucleic acid sequence of any one of claims 40-51, wherein the second polypeptide and the third polypeptide are directly fused, and joined to the first polypeptide by a linker.

### Claim 55 (depends on 53, 54)

The nucleic acid sequence of any one of claims 53-54, wherein the linker is a peptide linker, preferably a peptide linker comprising 5 to 30 amino acids, more preferably 5 amino acids, 10 amino acids, or 15 amino acids.

### Claim 56 (depends on 56)

The nucleic acid sequence of claim 56, wherein the peptide linker comprises a G4S3 linker.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

A vector comprising the nucleic acid sequence of any one of claims 1-56.

### Claim 58 (depends on 57)

The vector of claim 57, further comprising a promoter, preferably a promoter functional in a mammalian cell.

### Claim 59 (depends on 57, 58)

A T cell transfected with the vector of any one of claims 57-58.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

An engineered T cell comprising the nucleic acid sequence of any one of claims 1-56, or the vector of any one of claims 57-58.

### Claim 61 (depends on 60)

A pharmaceutical composition comprising the engineered T cell of claim 60, and a pharmaceutically acceptable carrier.

### Claim 62

A method of treating a cancer expressing a target antigen in an individual in need thereof, comprising administering to the individual an engineered T cell comprising a nucleic acid sequence encoding a Trifunctional T cell-antigen coupler (Tri-TAC) comprising:
(a) a first polynucleotide sequence encoding a ligand that selectively binds the target antigen;
(b) a second polynucleotide sequence encoding a UCHT1 ligand with a Y182T mutation comprising an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 26 that binds a protein associated with a T cell receptor (TCR) complex; and
(c) a third polynucleotide sequence encoding a TCR signaling domain polypeptide.

### Claim 63

A method of treating a cancer expressing a target antigen in an individual in need thereof, comprising administering to the individual an engineered T cell comprising a nucleic acid sequence encoding a Trifunctional T cell-antigen coupler (Tri-TAC) comprising:
(a) a first polynucleotide sequence encoding a ligand that selectively binds the target antigen;
(b) a second polynucleotide sequence encoding a humanized variant of UCHT1 (huUCHT1) ligand comprising an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 29 that binds a protein associated with a T cell receptor (TCR) complex; and
(c) a third polynucleotide sequence encoding a TCR signaling domain polypeptide.

### Claim 64

A method of treating a cancer expressing a target antigen in an individual in need thereof, comprising administering to the individual an engineered T cell comprising a nucleic acid sequence encoding a T cell-antigen coupler (Tri-TAC) comprising:
(a) a first polynucleotide sequence encoding a ligand that selectively binds the target antigen;
(b) a second polynucleotide sequence encoding a humanized variant UCHT1 (huUCHT1) ligand with a Y177T mutation comprising an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 28 that binds a protein associated with a T cell receptor (TCR) complex; and
(c) a third polynucleotide sequence encoding a TCR signaling domain polypeptide.

### Claim 65 (depends on 62)

The nucleic acid sequence of claim 62, wherein the amino acid sequence comprises SEQ ID NO: 26.

### Claim 66 (depends on 63)

The nucleic acid sequence of claim 63, wherein the amino acid sequence comprises SEQ ID NO: 29.

### Claim 67 (depends on 64)

The nucleic acid sequence of claim 64, wherein the amino acid sequence comprises SEQ ID NO: 28.

### Claim 68 (depends on 62, 63, 64, 65, 66, 67)

The method of any one of claims 62-67, wherein the ligand specifically binds the target antigen.

### Claim 69 (depends on 62, 63, 64, 65, 66, 67, 68)

The method of any one of claims 62-68, wherein the ligand is an ankyrin repeat (DARPin) polypeptide.

### Claim 70 (depends on 62, 63, 64, 65, 66, 67)

The method of any one of claims 62-67, wherein the ligand is a single chain variable fragment (scFv).

### Claim 71 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70)

The method of any one of claims 62-70, wherein the target antigen is a tumor antigen.

### Claim 72 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

The method of any one of claims 62-71, wherein the antigen is a HER-2 antigen.

### Claim 73 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

The method of any one of claims 62-71, wherein the antigen is a BCMA antigen.

### Claim 74 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 62-73, wherein the protein associated with a TCR complex is CD3, preferably CD3ε.

### Claim 75 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 62-74, wherein the TCR signaling domain polypeptide comprises a transmembrane domain and a cytosolic domain.

### Claim 76 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

The method of any one of claims 62-75, wherein the TCR signaling domain polypeptide comprises a transmembrane domain and a cytosolic domain of a TCR co-receptor.

### Claim 77 (depends on 76)

The method of claim 76, wherein the TCR co-receptor is CD4.

### Claim 78 (depends on 76)

The method of claim 76, wherein the TCR co-receptor is CD8, preferably CD8α.

### Claim 79 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The method of any one of claims 62-78, wherein the first polypeptide, the second polypeptide, and the third polypeptide are directly fused.

### Claim 80 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The method of any one of claims 62-78, wherein the first polypeptide and the second polypeptide are directly fused, and joined to the third polypeptide by a linker.

### Claim 81 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The method of any one of claims 62-78, wherein the second polypeptide and the third polypeptide are directly fused, and joined to the first polypeptide by a linker.

### Claim 82 (depends on 80, 81)

The method of any one of claims 80-81, wherein the linker is a peptide linker, preferably a peptide linker comprising 5 to 30 amino acids, more preferably 5 amino acids, 10 amino acids, or 15 amino acids.

### Claim 83 (depends on 82)

The method of claim 82, wherein the peptide linker comprises a G4S3 linker.

### Claim 84 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The method of any one of claims 62-83, wherein the cancer is a solid cancer or a liquid cancer.

### Claim 85 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84)

The method of any one of claims 62-84, wherein the cancer is a lung cancer, a breast cancer, a colon cancer, multiple myeloma, glioblastoma, gastric cancer, ovarian cancer, stomach cancer, colorectal cancer, urothelial cancer, endometrial cancer, or a melanoma.

### Claim 86

A method of treating a cancer expressing a HER-2 antigen in an individual in need thereof, comprising administering to the individual an engineered T cell comprising a nucleic acid sequence encoding an anti-HER-2 Trifunctional T cell-antigen coupler (anti-HER-2 Tri-TAC) comprising:
(a) a first polynucleotide sequence encoding a ligand that selectively binds the HER-2 antigen;
(b) a second polynucleotide sequence encoding:
(i) a UCHT1 ligand with a Y182T mutation comprising an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 26 that binds a protein associated with a T cell receptor (TCR) complex,
(ii) a humanized variant of UCHT1 (huUCHT1) ligand comprising an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 29 that binds a protein associated with a T cell receptor (TCR) complex, or
(iii) a humanized variant of UCHT1 (huUCHT1) ligand with a Y177T mutation comprising an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 28 that binds a protein associated with a T cell receptor (TCR) complex; and
(c) a third polynucleotide sequence encoding a TCR signaling domain polypeptide.

### Claim 87 (depends on 86)

The nucleic acid sequence of claim 86, wherein the amino acid sequence comprises SEQ ID NO: 26.

### Claim 88 (depends on 86)

The nucleic acid sequence of claim 86, wherein the amino acid sequence comprises SEQ ID NO: 29.

### Claim 89 (depends on 86)

The nucleic acid sequence of claim 86, wherein the amino acid sequence comprises SEQ ID NO: 28.

### Claim 90 (depends on 86, 87, 88, 89)

The method of any one of claims 86-89, wherein the ligand specifically binds the HER-2 antigen.

### Claim 91 (depends on 86, 87, 88, 89, 90)

The method of any one of claims 86-90, wherein the ligand is an ankyrin repeat (DARPin) polypeptide.

### Claim 92 (depends on 86, 87, 88, 89, 90, 91)

The method of any one of claims 86-91, wherein the protein associated with a TCR complex is CD3, preferably CD3ε.

### Claim 93 (depends on 86, 87, 88, 89, 90, 91, 92)

The method of any one of claims 86-92, wherein the TCR signaling domain polypeptide comprises a transmembrane domain and a cytosolic domain.

### Claim 94 (depends on 86, 87, 88, 89, 90, 91, 92, 93)

The method of any one of claims 86-93, wherein the TCR signaling domain polypeptide comprises a transmembrane domain and a cytosolic domain of a TCR co-receptor.

### Claim 95 (depends on 94)

The method of claim 94, wherein the TCR co-receptor is CD4.

### Claim 96 (depends on 94)

The method of claim 94, wherein the TCR co-receptor is CD8, preferably CD8α.

### Claim 97 (depends on 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The method of any one of claims 86-96, wherein the first polypeptide, the second polypeptide, and the third polypeptide are directly fused.

### Claim 98 (depends on 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The method of any one of claims 86-96, wherein the first polypeptide and the second polypeptide are directly fused, and joined to the third polypeptide by a linker.

### Claim 99 (depends on 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The method of any one of claims 86-96, wherein the second polypeptide and the third polypeptide are directly fused, and joined to the first polypeptide by a linker.

### Claim 100 (depends on 98, 99)

The method of any one of claims 98-99, wherein the linker is a peptide linker, preferably a peptide linker comprising 5 to 30 amino acids, more preferably 5 amino acids, 10 amino acids, or 15 amino acids.

### Claim 101 (depends on 100)

The method of claim 100, wherein the peptide linker comprises a G4S3 linker.

### Claim 102 (depends on 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101)

The method of any one of claims 86-101, wherein the cancer is a solid cancer or a liquid cancer.

### Claim 103 (depends on 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102)

The method of any one of claims 86-102, wherein the cancer is a lung cancer, a breast cancer, multiple myeloma, glioblastoma, gastric cancer, ovarian cancer, stomach cancer, colorectal cancer, urothelial cancer, endometrial cancer, or a colon cancer.

### Claim 104

A method of treating a cancer expressing a BCMA antigen in an individual in need thereof, comprising administering to the individual an engineered T cell comprising a nucleic acid sequence encoding an anti-BCMA Trifunctional T cell-antigen coupler (anti-BCMA Tri-TAC) comprising:
(a) a first polynucleotide sequence encoding a ligand that selectively binds the BCMA antigen;
(b) a second polynucleotide sequence encoding:
(i) a UCHT1 ligand with a Y182T mutation comprising an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 26 that binds a protein associated with a T cell receptor (TCR) complex,
(ii) a humanized variant of UCHT1 (huUCHT1) ligand comprising an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 29 that binds a protein associated with a T cell receptor (TCR) complex, or
(iii) a humanized variant of UCHT1 (huUCHT1) ligand with a Y177T mutation comprising an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 28 that binds a protein associated with a T cell receptor (TCR) complex; and
(c) a third polynucleotide sequence encoding a TCR signaling domain polypeptide.

### Claim 105 (depends on 104)

The nucleic acid sequence of claim 104, wherein the amino acid sequence comprises SEQ ID NO: 26.

### Claim 106 (depends on 104)

The nucleic acid sequence of claim 104, wherein the amino acid sequence comprises SEQ ID NO: 29.

### Claim 107 (depends on 104)

The nucleic acid sequence of claim 104, wherein the amino acid sequence comprises SEQ ID NO: 28.

### Claim 108 (depends on 104, 105, 106, 107)

The method of any one of claims 104-107, wherein the ligand specifically binds the BCMA antigen.

### Claim 109 (depends on 104, 105, 106, 107, 108)

The method of any one of claims 104-108, wherein the ligand is a single chain variable fragment (scFv).

### Claim 110 (depends on 104, 105, 106, 107, 108, 109)

The method of any one of claims 104-109, wherein the protein associated with a TCR complex is CD3, preferably CD3ε.

### Claim 111 (depends on 104, 105, 106, 107, 108, 109, 110)

The method of any one of claims 104-110, wherein the TCR signaling domain polypeptide comprises a transmembrane domain and a cytosolic domain.

### Claim 112 (depends on 104, 105, 106, 107, 108, 109, 110, 111)

The method of any one of claims 104-111, wherein the TCR signaling domain polypeptide comprises a transmembrane domain and a cytosolic domain of a TCR co-receptor.

### Claim 113 (depends on 112)

The method of claim 112, wherein the TCR co-receptor is CD4.

### Claim 114 (depends on 112)

The method of claim 112, wherein the TCR co-receptor is CD8, preferably CD8α.

### Claim 115 (depends on 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114)

The method of any one of claims 104-114, wherein the first polypeptide, the second polypeptide, and the third polypeptide are directly fused.

### Claim 116 (depends on 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114)

The method of any one of claims 104-114, wherein the first polypeptide and the second polypeptide are directly fused, and joined to the third polypeptide by a linker.

### Claim 117 (depends on 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114)

The method of any one of claims 104-114, wherein the second polypeptide and the third polypeptide are directly fused, and joined to the first polypeptide by a linker.

### Claim 118 (depends on 116, 117)

The method of any one of claims 116-117, wherein the linker is a peptide linker, preferably a peptide linker comprising 5 to 30 amino acids, more preferably 5 amino acids, 10 amino acids, or 15 amino acids.

### Claim 119 (depends on 118)

The method of claim 118, wherein the peptide linker comprises a G4S3 linker.

### Claim 120 (depends on 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119)

The method of any one of claims 104-119, wherein the cancer is a solid cancer or a liquid cancer.

### Claim 121 (depends on 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120)

The method of any one of claims 104-120, wherein the cancer is a multiple myeloma.
